Closed · RFA-OD-20-021 · CFDA 93.121;93.233;93.273;93.286;93.307;93.310;93.350;93.837;93.839;93.840;93.846;93.865;93.879 · Discretionary

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
September 18, 2020
Close date
-
Expected awards

The verdict

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

Varies
award range
Closed
application status
93.121;93.233;93.273;93.286;93.307;93.310;93.350;93.837;93.839;93.840;93.846;93.865;93.879
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Emergency Awards RADx-RAD: Novel Biosensing f… is closed (last close September 18, 2020). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 18, 2020

Posted Aug 6 Closes Sep 18

Est. Total Funding

$3,000,000

Instrument

Grant

Description

The goal of this RFA is to solicit Fast Track STTR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. Oral biosensing technologies may target a wealth of biological, chemical (e.g., VOCs) and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity.

Small-business / for-profit corridor · RFA-OD-20-021

Emergency Awards RADx-RAD: Novel Biosensing f… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health · Income Security and Social Services (ED;HL;ISS). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

Emergency Awards RADx-RAD: Novel Biosensing f… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.121;93.233;93.273;93.286;93.307;93.310;93.350;93.837;93.839;93.840;93.846;93.865;93.879 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants